Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
Search
Advanced Search
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

3
results for

"SGLT2 inhibitor"

Article category

Keywords

More +

Publication year

"SGLT2 inhibitor"

Reply to Correspondence

Reply to correspondence on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”
Yang-Hsiang Lin, Ching-Chih Hu, Chih-Lang Lin
Clin Mol Hepatol 2026;32(3):e434-e436.
Published online February 5, 2026
DOI: https://doi.org/10.3350/cmh.2026.0123
  • 1,457 View
  • 43 Download
Correspondences
Correspondence to editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”
Jonggi Choi, Raymond T. Chung
Clin Mol Hepatol 2026;32(3):e372-e374.
Published online January 27, 2026
DOI: https://doi.org/10.3350/cmh.2026.0046
  • 1,422 View
  • 16 Download
Reaffirming the role of SGLT2 inhibitors in slowing fibrotic progression in MASLD: Correspondence to editorial on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”
Jonggi Choi, Raymond T. Chung
Clin Mol Hepatol 2026;32(3):e369-e371.
Published online January 9, 2026
DOI: https://doi.org/10.3350/cmh.2025.1476
  • 1,198 View
  • 40 Download
First First Prev Prev
Page of 1
Next Next Last Last
Clin Mol Hepatol : Clinical and Molecular Hepatology
Twitter